Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Rhabdoid Tumor 1Recurrence 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Multiple Myeloma 1Medulloblastoma 1Glioma 1Ependymoma 1Choroid Plexus Carcinoma 1Brain Neoplasms 1

Interventions

Dexamethasone 14Rituximab 6Cytarabine 5venetoclax 4Lenalidomide 4Bortezomib 4Bendamustine Hydrochloride 4selinexor 3pomalidomide 3pembrolizumab 3ibrutinib 3fludarabine 3carfilzomib 3Paclitaxel 3Gemcitabine 3Drug Therapy 3Cyclophosphamide 3Calcium Dobesilate 3ixazomib 2gilteritinib 2fludarabine phosphate 2elotuzumab 2daratumumab 2belinostat 2Tablets 2Surveys and Questionnaires 2Panobinostat 2Oxaliplatin 2Granulocyte Colony-Stimulating Factor 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Recurrence × thymoglobulin × Clear all
NCT00874315 2015-10-16

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.

Nationwide Children's Hospital

Phase 2 Withdrawn
CNS

Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡